Reminders

Changing Life Sciences Value Chain

Archives for March 2010 « Recent Articles

OfflinePhoto of Dr. Alan S. Louie

Genomic Screening at the Crossroads

By Dr. Alan S. Louie – 4 Comments

Monday's announcement that a federal court has ruled that patents on two cancer genes held by Myriad Genetics are invalid has the potential to be game changing in a major way if upheld.  As we all know, patents are the life's blood of the life science industry, core to perceived value, and a primary requirement for access to capital.  In this case, gene patents are different from drug patents and the core of the ruling presumes to determine that a gene is natural and not an invention and therefore


OfflinePhoto of Eric Newmark

With Healthcare legislation well on its way to ultimate approval and implementation,  the winds are now calming and its becoming clearer what the tornado has left behind for the pharmaceutical industry. Many had feared it would result in permanent widespread damage, but it appears the storm may actually have carved a path toward greener pastures for the industry.


OfflinePhoto of Eric Newmark

Supply Chain Security: Slowly Improving

By Eric Newmark

Five years ago, many in the industry were convinced that wireless technologies would ultimately deliver the lion share of supply chain security improvements in the life sciences, leading to the eventual elimination of most counterfeit drugs from US-based distribution channels. However, RFID and related wireless technologies have been slow to reach critical mass due to a mixture of lacking standards, cost issues, and reliability concerns. At the beginning 2009, 43% of companies were assessing RFID (doubling


OfflinePhoto of Dr. Alan S. Louie

Sitting here at the SAS analysts conference in Colorado, an elegant representation of the decision analytics value chain was presented.  Beginning with standardized reports and moving through automated alerts en route to predictive analytics and finally optimization, the decision analytics value chain characterizes the maturity of tools available to decision makers at all levels within an organization.  In our discussions with industry leaders across the entire health industry spectrum, their abil


OfflinePhoto of Dr. Alan S. Louie

Imminent: Genomic Information at the Point of Care

By Dr. Alan S. Louie

While we regularly hear announcements regarding the identification of genetic variants associated with disease, it is also clear that current regulatory approval practices ensure that today’s knowledge will not translate into commercial practice for years, based on current industry practices.  While definitive proof of both safety and efficacy are driving this practice, the availability of current knowledge to practicing physicians has the ability to directly improve medical care, while potential



Viewed 701,013 times